Rifaximin and Crohn's disease
In a recent article, Longman and Swaminath analyzed our paper on the use of rifaximin in patients with moderately active Crohn's disease (CD). Here we report some considerations concerning their article. The exploratory post-hoc subgroup analysis showed that early-stage disease and, differently from that written by Longman and Swaminath, also colonic involvement seemed to be associated with a significant higher efficacy of rifaximin-EIR 800 mg twice daily. Early-stage disease is generally considered as the more easily treatable phase of CD, and the better response to rifaximin in Crohn's colitis is in accordance with the high concentration of bacteria in the colon. In addition, patients with C reactive protein level > 5 mg/L achieved remission more significantly than patients with normal values, thus suggesting that the symptoms were probably caused by inflammation instead of by non-inflammatory causes. We also analyze the role of rifaximin against gut bacteria and the clinical situations that could obtain the best results from antibiotics.
| Errataetall: |
CommentOn: World J Gastroenterol. 2013 Mar 14;19(10):1513-6. - PMID 23539531 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
World journal of gastroenterology - 19(2013), 42 vom: 14. Nov., Seite 7487-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prantera, Cosimo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Infective Agents |
|---|
| Anmerkungen: |
Date Completed 30.04.2014 Date Revised 21.10.2021 published: Print CommentOn: World J Gastroenterol. 2013 Mar 14;19(10):1513-6. - PMID 23539531 Citation Status MEDLINE |
|---|
| doi: |
10.3748/wjg.v19.i42.7487 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM232911568 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM232911568 | ||
| 003 | DE-627 | ||
| 005 | 20231224094009.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3748/wjg.v19.i42.7487 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0776.xml |
| 035 | |a (DE-627)NLM232911568 | ||
| 035 | |a (NLM)24259983 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prantera, Cosimo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rifaximin and Crohn's disease |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.04.2014 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: World J Gastroenterol. 2013 Mar 14;19(10):1513-6. - PMID 23539531 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In a recent article, Longman and Swaminath analyzed our paper on the use of rifaximin in patients with moderately active Crohn's disease (CD). Here we report some considerations concerning their article. The exploratory post-hoc subgroup analysis showed that early-stage disease and, differently from that written by Longman and Swaminath, also colonic involvement seemed to be associated with a significant higher efficacy of rifaximin-EIR 800 mg twice daily. Early-stage disease is generally considered as the more easily treatable phase of CD, and the better response to rifaximin in Crohn's colitis is in accordance with the high concentration of bacteria in the colon. In addition, patients with C reactive protein level > 5 mg/L achieved remission more significantly than patients with normal values, thus suggesting that the symptoms were probably caused by inflammation instead of by non-inflammatory causes. We also analyze the role of rifaximin against gut bacteria and the clinical situations that could obtain the best results from antibiotics | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a Intestinal microbiota | |
| 650 | 4 | |a Non-absorbable antibiotic | |
| 650 | 4 | |a Rifaximin | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 650 | 7 | |a Rifamycins |2 NLM | |
| 700 | 1 | |a Scribano, Maria Lia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of gastroenterology |d 1997 |g 19(2013), 42 vom: 14. Nov., Seite 7487-8 |w (DE-627)NLM117065250 |x 2219-2840 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2013 |g number:42 |g day:14 |g month:11 |g pages:7487-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3748/wjg.v19.i42.7487 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2013 |e 42 |b 14 |c 11 |h 7487-8 | ||